SOUTH KINGSTOWN –MindImmune Therapeutics Inc. has entered into agreements with H. Lundbeck A/S to acquire programs and will develop candidates from these programs as novel therapeutics to treat neuropathic pain and Huntington’s disease, the company announced Wednesday.
The programs target two neuroinflammation targets: P2X7 receptors and KMO, an enzyme in the neuroimmune kynurenine-signaling pathway, according to the company.
Beyond Cash Donations: How New Forms of Giving Are Transforming Not-for-Profit Accounting
Evolving Funding Landscape for Not-for-Profits Not-for-profit organizations are being asked to do more with less,…
Learn More
MindImmune said that preclinical observations indicate that blocking the P2X7 receptor may block neuroinflammation that could reduce neuropathic pain, a result of nerve damage.
The company said that preclinical and clinical evidence indicates that brain damage from Huntington’s disease is caused in part by disruption of the neuroimmune kynurenine signaling pathway. The KMO inhibitor program is being developed to dampen the process and slow or prevent the progressive neurological deterioration of patients with Huntington’s disease.
As part of the acquisition, H. Lundbeck will receive equity in MindImmune and receive payments and royalties for both programs based on their progression.
“We greatly appreciate the confidence Lundbeck has shown in MindImmune,” said Stevin Zorn, president and CEO of MindImmune in a statement. “We are committed to driving these programs forward and bringing product candidates into the clinic with the potential to transform the lives of patients with chronic neuropathic pain and Huntington’s disease.”
The company said the acquisition complements its program to target neuroinflammation to halt Alzheimer’s disease and other neuro-degenerative disorders.
”Lundbeck focuses on treatments for depression, schizophrenia, Alzheimer’s disease and Parkinson’s disease, so we are pleased to divest these two promising programs that falls outside our focus areas in line with our strategy. This agreement ensures the continued development of the programs building on our research and hopefully leading to new and better treatments for patients,” stated Kim Andersen, senior vice president, research, at Lundbeck.
Chris Bergenheim is the PBN web editor.
